Matsumoto Hiroaki, Matsumoto Atsushi, Miyata Shiro, Tomogane Yusuke, Minami Hiroaki, Masuda Atsushi, Yamaura Ikuya, Yoshida Yasuhisa, Hirata Yutaka
Department of Neurosurgery, Cerebrovascular Research Institute, Eisyokai Yoshida Hospital, Kobe , Hyogo , Japan.
Department of Neurology, Cerebrovascular Research Institute, Eisyokai Yoshida Hospital, Kobe , Hyogo , Japan.
Neurosurgery. 2024 Jan 1;94(1):80-89. doi: 10.1227/neu.0000000000002649. Epub 2023 Aug 28.
Chronic subdural hematoma (CSDH) sometimes recurs after surgical treatment and requires reoperation. In Japan, Japanese herbal medicines (Kampo), such as Goreisan and Saireito, have been used as adjunctive therapies to prevent the recurrence of CSDH. However, no prospective randomized study has proven the efficacy of Kampo medicine in all patients. To investigate whether Goreisan and Saireito reduce the postoperative recurrence of CSDH in a prospective randomized study.
Between April 2017 and July 2019, a total of 118 patients who underwent initial burr hole surgery for CSDH were randomly assigned to the following 3 groups: (1) Goreisan for 3 months (Group G), (2) Saireito for 3 months (Group S), and (3) no medication (Group N). The primary end point was symptomatic recurrence within 3 months postoperatively, and the secondary end point was complications associated with the administration of Kampo medicine.
Among 118 patients, 114 (Group N, n = 39; Group G, n = 37; and Group S, n = 38) were included in our analysis. In this study, byakujutsu (containing Atractylodes rhizome ) Goreisan and Saireito were used, unlike other prospective randomized studies in which sojutsu (containing Atractylodes lancea rhizome) Goreisan was used. The overall recurrence rate was 11.4% (13/114: 10 for Group N, 2 for Group G, and 1 for Group S). The recurrence rate of Group G was significantly lower than that of Group N (5.4% vs 25.6%; P = .043). The recurrence rate of Group S was also significantly lower than that of Group N (2.6% vs 25.6%; P = .02). No patients developed complications associated with the administration of Kampo medicine.
This is the first study to show that Kampo medicine reduced the recurrence rate of CSDH in an overall population. This study demonstrated that byakujutsu Goreisan and Saireito may have favorable effects, unlike other studies, because byakujutsu has stronger anti-inflammatory activity than sojutsu.
慢性硬膜下血肿(CSDH)在手术治疗后有时会复发,需要再次手术。在日本,诸如桂枝茯苓丸和柴苓汤等汉方药已被用作预防CSDH复发的辅助疗法。然而,尚无前瞻性随机研究证实汉方药对所有患者均有效。为了在前瞻性随机研究中调查桂枝茯苓丸和柴苓汤是否能降低CSDH术后复发率。
在2017年4月至2019年7月期间,共有118例因CSDH接受初次钻孔手术的患者被随机分为以下3组:(1)服用桂枝茯苓丸3个月(G组),(2)服用柴苓汤3个月(S组),(3)不服用药物(N组)。主要终点是术后3个月内出现症状性复发,次要终点是与服用汉方药相关的并发症。
118例患者中,114例(N组39例、G组37例、S组38例)纳入我们的分析。在本研究中,使用的是白术(含白术根茎)桂枝茯苓丸和柴苓汤,这与其他使用苍术(含茅苍术根茎)桂枝茯苓丸的前瞻性随机研究不同。总体复发率为11.4%(114例中的13例:N组10例、G组2例、S组1例)。G组的复发率显著低于N组(5.4%对25.6%;P = 0.043)。S组的复发率也显著低于N组(2.6%对25.6%;P = 0.02)。没有患者出现与服用汉方药相关的并发症。
这是第一项表明汉方药可降低总体人群中CSDH复发率的研究。本研究表明,白术桂枝茯苓丸和柴苓汤可能具有良好效果,这与其他研究不同,因为白术的抗炎活性比苍术更强。